A Phase 1, Randomized, Active-Comparator/Placebo-Controlled, Observer-Blinded Trial of the Safety, Tolerability, and Immunogenicity of 20 mg, 60 mg, and 200 mg of Meningococcal Group B rLP2086 Vaccine in Healthy Toddlers Aged 18 to 36 Months
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2014
At a glance
- Drugs PF 5212366 (Primary)
- Indications Meningococcal group B infections
- Focus Adverse reactions
- Sponsors Wyeth
- 11 May 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 03 Dec 2006 New trial record.